The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017

Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017

June 5, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Pfizer Inc. has hiked the price of nearly a hundred drugs by an average of 20 percent so far this year in the U.S., the Financial Times reported on Friday.

You Might Also Like
  • Pfizer Hikes U.S. Prices for More Than 100 Drugs on Jan. 1
  • Pfizer Plans to Increase U.S. Drug Prices in January
  • Transatlantic Divide: How U.S. Pays Three Times More for Drugs

The U.S. drug maker raised the list price of 91 medicines—including that of its erectile dysfunction treatment, Viagra, and its pain drug, Lyrica—on June 1 by 5–13%, according to figures seen by the Financial Times.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pfizer had also raised prices in January and, including those hikes, the average price of many of its drugs has risen by 20 percent this year, the FT said.

“For Pfizer’s U.S. biopharma business, as of the first quarter, the weighted average net selling price increase year-to-date is 4%,” a spokesman for Pfizer says, referring to prices after discounts and rebates, rather than list prices.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Drug pricing has become a contentious issue as a wave of new treatments for cancer and other serious conditions reach the market, some costing tens or hundreds of thousands of dollars.

But the row is particularly fierce in the U.S., where prices are higher than in Europe and where there have been highly publicized price hikes of some older drugs, such as Mylan’s EpiPen.

In a bid to placate U.S. payers, patients and politicians, several companies, both domestic and foreign, have pledged to limit price rises.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

French drugmaker Sanofi in May said it would not raise prices beyond the rate of healthcare inflation, which would cap hikes at 5.4% this year.

Other companies such as AbbVie, Allergan and Novo Nordisk have said they would raise prices in the single-digit percentage range this year.

 

Filed Under: Drug Updates, Pharma Co. News Tagged With: cost, drug costs, drug pricing, Pfizer Inc.

You Might Also Like:
  • Pfizer Hikes U.S. Prices for More Than 100 Drugs on Jan. 1
  • Pfizer Plans to Increase U.S. Drug Prices in January
  • Transatlantic Divide: How U.S. Pays Three Times More for Drugs
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)